SOPHiA GENETICS SA·4

Apr 28, 4:03 PM ET

Menu Philippe 4

4 · SOPHiA GENETICS SA · Filed Apr 28, 2026

Research Summary

AI-generated summary of this filing

Updated

SOPHiA GENETICS (SOPH) CMO Philippe Menu Sells 5,000 Shares

What Happened
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA (SOPH), sold 5,000 shares on 2026-04-27. The reported weighted-average price was $4.82 per share (range $4.75–$4.89), for total proceeds of approximately $24,089. This was a sale (not a purchase); the filing notes the sale was made under a pre-established Rule 10b5-1 trading plan.

Key Details

  • Transaction date: 2026-04-27; filing date: 2026-04-28 (filed within the Form 4 reporting window).
  • Price: weighted average $4.82; reported trade prices ranged from $4.75 to $4.89.
  • Shares sold: 5,000; proceeds ≈ $24,089.
  • Shares owned after transaction: not disclosed in the information provided.
  • Footnotes: F1 — transaction made pursuant to a duly adopted Rule 10b5-1(c) plan; F2 — the $4.82 is a weighted average and the filer can provide a per-price breakdown on request.
  • Timeliness: filing appears timely (next business day).

Context
Sales made under 10b5-1 plans are pre-planned and commonly used to avoid trading-window issues; they are often routine and do not necessarily reflect new views about the company. The dollar amount here is modest (~$24K), so this single sale is unlikely to materially affect ownership or signal major insider conviction. Retail investors should weigh insider trades alongside other fundamentals and news.

Insider Transaction Report

Form 4
Period: 2026-04-27
Menu Philippe
Chief Medical Officer
Transactions
  • Sale

    Ordinary Shares

    [F1][F2]
    2026-04-27$4.82/sh5,000$24,089261,388 total
Footnotes (2)
  • [F1]Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.75 to $4.89, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu|2026-04-28

Documents

1 file
  • 4
    wk-form4_1777406606.xmlPrimary

    FORM 4